warning

Alert: Because flu cases are on the rise, children 12 and younger will be restricted from visiting hospitals and certain inpatient facilities. Learn more.

Research and Clinical Trials

Title  
Genentech WO29636: A Phase III, Open-Label, Multicenter, Randomized Study of Atezolizumab (ANTI-PD L1 Antibody) versus Observation as Adjuvant Therapy in Patients with High Risk Muscle Invasive Urothelial Carcinoma after Surgical Resection
Brief Description  
The primary efficacy objective for this study is to evaluate the efficacy of adjuvant MPDL3280A treatment in patients with PD- L1 selected muscle invasive bladder cancer (MIBC), as measured by disease-free survival (DFS)
Who may be Eligible  
Please contact us for eligibility criteria.
Speciality/Disorder  
Urinary Bladder
Status  
OPEN
Start Date  
10/28/2015
IRB Number  
00012970
Principal Investigator  
Burgess, Earle Frederick
Contact Name  
Neil L West

For More Information, Contact  Neil  L, West
Phone:  704-863-6187 Fax:    
Email:  neil.west@carolinashealthcare.org
Address:101 WT Harris Blvd Bldg 1000 Suite 1214 Charlotte, NC 28262
Close